The Synergistic Effect of Sorafenib and TNF-α Inhibitor on Hepatocellular Carcinoma

Overview

Journal EBioMedicine

Specialty Biomedical Engineering

Date 2019 Jan 18

PMID 30651221

Citations 6

Authors

Mingda Wang

Mengchao Wu

Tian Yang

Affiliations

Soon will be listed here.

Citing Articles

Diversified applications of hepatocellular carcinoma medications: molecular-targeted, immunotherapeutic, and combined approaches.

Chen H, Liu H, Zhang X, Wang S, Liu C, An K Front Pharmacol. 2024; 15:1422033.

PMID: 39399471 PMC: 11467865. DOI: 10.3389/fphar.2024.1422033.

Zengshengping improves lung cancer by regulating the intestinal barrier and intestinal microbiota.

Sun E, Meng X, Kang Z, Gu H, Li M, Tan X Front Pharmacol. 2023; 14:1123819.

PMID: 36992837 PMC: 10040556. DOI: 10.3389/fphar.2023.1123819.

The Cuproptosis-Related Long Noncoding RNA Signature Predicts Prognosis and Immune Cell Infiltration in Hepatocellular Carcinoma.

Li Y, Song K, Zheng W J Oncol. 2023; 2023:9557690.

PMID: 36891559 PMC: 9988371. DOI: 10.1155/2023/9557690.

Relationship Between Serum Inflammatory Factor Levels and Differentiated Thyroid Carcinoma.

Zhang X, Li S, Wang J, Liu F, Zhao Y Technol Cancer Res Treat. 2021; 20:1533033821990055.

PMID: 33752541 PMC: 8093610. DOI: 10.1177/1533033821990055.

Preclinical Pharmacokinetic Interaction and Histopathological Analyses of on Sorafenib in Rats.

Ting C, Cheng Y, Tsai T ACS Omega. 2021; 6(4):3060-3067.

PMID: 33553923 PMC: 7860071. DOI: 10.1021/acsomega.0c05461.

References

Lewis A, Varghese S, Xu H, Alexander H . Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med. 2006; 4:48. PMC: 1660548. DOI: 10.1186/1479-5876-4-48. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Cheng A, Kang Y, Chen Z, Tsao C, Qin S, Kim J . Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2008; 10(1):25-34. DOI: 10.1016/S1470-2045(08)70285-7. View

Bishayee A . The role of inflammation and liver cancer. Adv Exp Med Biol. 2014; 816:401-35. DOI: 10.1007/978-3-0348-0837-8_16. View

Mikami S, Mizuno R, Kosaka T, Saya H, Oya M, Okada Y . Expression of TNF-α and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas. Int J Cancer. 2014; 136(7):1504-14. DOI: 10.1002/ijc.29137. View